Table 3– Hazard ratios for end-points in the ARTEMIS-IPF study according to low versus high baseline serum lysyl oxidase-like 2 (sLOXL2)
End-pointsEvent rateHR (95% CI) for high sLOXL2p-value
Low sLOXL2High sLOXL2
ARTEMIS-IPF#
 Disease progression10/54 (19)8/15 (53)5.41 (1.65–17.73)0.005
 Lung function decline5/54 (9)4/15 (27)7.64 (1.21–48.25)0.031
 Respiratory hospitalisation6/54 (11)6/15 (40)5.35 (1.19–24.00)0.029
 Mortality5/54 (9)4/15 (27)1.87 (0.28–12.45)0.517
GAP
 Disease progression22/35 (63)28/35 (80)1.78 (1.01–3.11)0.045
 Lung function decline13/35 (37)16/35 (46)1.43 (0.69–2.98)0.337
 Mortality10/35 (29)16/35 (46)1.77 (0.80–3.89)0.159
 Mortality all subjects13/46 (28)30/58 (52)2.28 (1.18–4.38)0.014
  • Data are presented as n/N (%), unless otherwise stated. GAP: Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis study. #: each model for ARTEMIS-IPF included treatment assignment, 6-min walking distance and composite physiological index as covariates. : the first three models (disease progression, lung function decline and all-cause mortality) included only subjects with baseline spirometry (n=70). These models included no covariates. The second mortality model that included all subjects (n=104) included sex as a covariate.